Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA.
Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan, Ann Arbor, MI, USA; Faculty of Dentistry, National University of Singapore, Singapore.
Dent Mater. 2022 Mar;38(3):529-539. doi: 10.1016/j.dental.2021.12.141. Epub 2022 Jan 21.
Alveolar bone defects can be highly variable in their morphology and, as the defect size increases, they become more challenging to treat with currently available therapeutics and biomaterials. This investigation sought to devise a protocol for fabricating customized clinical scale and patient-specific, bioceramic scaffolds for reconstruction of large alveolar bone defects.
Two types of calcium phosphate (CaP)-based bioceramic scaffolds (alginate/β-TCP and hydroxyapatite/α-TCP, hereafter referred to as hybrid CaP and Osteoink™, respectively) were designed, 3D printed, and their biocompatibility with alveolar bone marrow stem cells and mechanical properties were determined. Following scaffold optimization, a workflow was developed to use cone beam computed tomographic (CBCT) imaging to design and 3D print, defect-specific bioceramic scaffolds for clinical-scale bone defects.
Osteoink™ scaffolds had the highest compressive strength when compared to hybrid CaP with different infill orientation. In cell culture medium, hybrid CaP degradation resulted in decreased pH (6.3) and toxicity to stem cells; however, OsteoInk™ scaffolds maintained a stable pH (7.2) in culture and passed the ISO standard for cytotoxicity. Finally, a clinically feasible laboratory workflow was developed and evaluated using CBCT imaging to engineer customized and defect-specific CaP scaffolds using OsteoInk™. It was determined that printed scaffolds had a high degree of accuracy to fit the respective clinical defects for which they were designed (0.27 mm morphological deviation of printed scaffolds from digital design).
From patient to patient, large alveolar bone defects are difficult to treat due to high variability in their complex morphologies and architecture. Our findings shows that Osteoink™ is a biocompatible material for 3D printing of clinically acceptable, patient-specific scaffolds with precision-fit for use in alveolar bone reconstructive procedures. Collectively, emerging digital technologies including CBCT imaging, 3D surgical planning, and (bio)printing can be integrated to address this unmet clinical challenge.
牙槽骨缺损在形态上可能高度多变,随着缺损尺寸的增加,用目前可用的治疗方法和生物材料治疗这些缺损变得更加具有挑战性。本研究旨在设计一种方案,用于制造定制的临床规模和患者特异性、生物陶瓷支架,以重建大型牙槽骨缺损。
设计了两种类型的基于磷酸钙(CaP)的生物陶瓷支架(藻酸盐/β-TCP 和羟基磷灰石/α-TCP,以下分别称为混合 CaP 和 Osteoink™),对其进行 3D 打印,并确定其与牙槽骨骨髓干细胞的生物相容性和机械性能。在支架优化后,开发了一种工作流程,使用锥形束计算机断层扫描(CBCT)成像来设计和 3D 打印针对临床规模骨缺损的特定缺陷的生物陶瓷支架。
与具有不同填充方向的混合 CaP 相比,Osteoink™支架具有最高的抗压强度。在细胞培养液中,混合 CaP 的降解导致 pH 值降低(6.3)和对干细胞的毒性;然而,OsteoInk™支架在培养中保持稳定的 pH 值(7.2),并通过了 ISO 细胞毒性标准。最后,使用 CBCT 成像开发并评估了一种临床可行的实验室工作流程,以使用 OsteoInk™设计定制的和特定于缺陷的 CaP 支架。结果表明,打印支架具有高度的准确性,可以适应各自的临床缺陷(打印支架与数字设计的形态偏差为 0.27 毫米)。
对于每个患者,由于其复杂形态和结构的高度变异性,大型牙槽骨缺损难以治疗。我们的研究结果表明,Osteoink™是一种生物相容性材料,可用于 3D 打印临床可接受的、患者特异性的支架,具有精密适配,可用于牙槽骨重建手术。总之,新兴的数字技术,包括 CBCT 成像、3D 手术规划和(生物)打印,可以集成在一起,以应对这一未满足的临床挑战。